Persson Oscar, Fletcher-Sandersjöö Alexander, Burström Gustav, Edström Erik, Elmi-Terander Adrian
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Front Neurol. 2019 Jul 26;10:814. doi: 10.3389/fneur.2019.00814. eCollection 2019.
Intramedullary spinal cord tumors (IMSCT) are rare entities and high-level evidence regarding optimal treatment is lacking. We aim to describe the demographics, histopathological distribution, onset symptoms, treatment strategies, and functional outcome for patients surgically treated for IMSCT. We performed a retrospective review of a consecutive population-based cohort of 95 patients who underwent surgery for intra- or juxtamedullary tumors at a single institution during the period 2004-2017. When gross total resection (GTR) was achieved, we found no case of local tumor recurrence even in the absence of adjuvant radio- or chemotherapy. Meanwhile, we found a 50% progression rate on long-term MRI follow-up in patients where only a partial resection was possible. At long-term follow-up, there was no significant alteration in functional status, while a significant reduction in share of patients reporting pain, compared to preoperative status, was identified. Poor preoperative functional status and postoperative tumor remnant were identified as individual risk factors for further functional decline. Gross total resection, with minimal post-operative neurological deterioration, is possible in the majority of the cases, especially in the presence of an identifiable resection plane between tumor and healthy spinal cord. Since long-term progression-free survival could be achieved by GTR without additional adjuvant treatment, we emphasize that low-grade tumors should not be subject to radiotherapy. Treatment of high-grade or diffusely infiltrating tumors, tumor remnants, or metastases should be individualized.
脊髓髓内肿瘤(IMSCT)较为罕见,目前缺乏关于最佳治疗方案的高级别证据。我们旨在描述接受手术治疗的IMSCT患者的人口统计学特征、组织病理学分布、起病症状、治疗策略及功能转归。我们对2004年至2017年期间在单一机构接受手术治疗的95例髓内或髓周肿瘤患者进行了基于人群的连续队列回顾性研究。当实现肿瘤全切除(GTR)时,即使未进行辅助放疗或化疗,我们也未发现局部肿瘤复发的病例。同时,我们发现对于仅能进行部分切除的患者,长期MRI随访显示其疾病进展率为50%。在长期随访中,患者的功能状态无显著改变,但与术前相比,报告疼痛的患者比例显著降低。术前功能状态差和术后肿瘤残留被确定为功能进一步下降的个体危险因素。在大多数病例中,尤其是肿瘤与健康脊髓之间存在可识别的切除平面时,可实现肿瘤全切除且术后神经功能恶化最小。由于通过GTR可实现长期无进展生存且无需额外辅助治疗,我们强调低级别肿瘤不应接受放疗。高级别或弥漫性浸润性肿瘤、肿瘤残留或转移瘤的治疗应个体化。